You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – Agilent Technologies announced on Monday it has received approval from the US Food and Drug Administration for its PD-L1 IHC 28-8 pharmDx as a companion diagnostic for expanded use in non-small cell lung cancer (NSCLC).
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.